EVG.L Share Price (EVG)

THERACRYF PLC will be holding the meeting Research and Development Update tomorrow at 13th Jun 2024 at 9:30am BST.

Investor Meet Company

STALICLA publishes on identification of first autism subgroup and matching treatment

Geneva, Switzerland, May 8, 2024 – STALICLA SA, a Swiss neuro precision biotech company, has provided proof-of-concept clinical data for DEPI (Databased Endophenotyping Patient Identification), its neuro precision discovery platform, enabling the identification of biological subgroups of patients with Autism Spectrum Disorder (ASD) and matching treatments, in a study published last week in Biomedicines

https://stalicla.com/media/news/stalicla-publishes-on-first-precision-medicine-study

Https://www.mdpi.com/2227-9059/12/5/991

Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage drug development company.

The Company is focused on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases.

Its core technology is Sulforadex, which is a method for synthesizing and stabilizing the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.

Its asset, SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive metastatic breast cancer. SFX-01 exploits sulforaphane's activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases.

Its pipeline includes breast cancer, glioblastoma, hematological malignancies, and analogues. It also has a licensing in neurodevelopmental disorders and schizophrenia.

MSM money

Well that transfer went smoothly, ...... not.

Bojo2020

Good to see you posting here :-)

All the best to you , and patience IS the Key here as usual ..